To investigate whether NFKBIE mutations can also affect the response to ibrutinib treatment in the clinical setting, we analyzed overall survival and cumulative risk of progression in a cohort of 229 ibrutinib-treated CLL patients for whom follow-up clinical data were available (Supplementary Table 1). This evidence concerns the gene NFKBIE and B-cell chronic lymphocytic leukemia.